全关节置换术后使用阿司匹林预防静脉血栓栓塞可降低死亡率
该回顾性研究纳入2000至2017年31,133例初次全关节置换术患者,按静脉血栓栓塞预防方案分为阿司匹林组(25.9%,8,061例)和非阿司匹林组(74.1%,23,072例)。阿司匹林使用与30天死亡风险降低(OR 0.39;p=0.020)及1年死亡风险降低(OR 0.51;p=0.004)独立相关。作者认为全关节置换术后使用阿司匹林预防静脉血栓栓塞可能降低死亡风险,骨科医生在选择静脉血栓栓塞预防药物时应了解阿司匹林的潜在额外获益。
要点
- 阿司匹林组30天死亡率0.1%,非阿司匹林组0.3%(p=0.004),非阿司匹林组30天死亡风险约为阿司匹林组的3倍。
- 阿司匹林组1年死亡率0.3%,非阿司匹林组0.7%(p<0.001),非阿司匹林组1年死亡风险约为阿司匹林组的2倍。
- 非阿司匹林组1年心脏相关死亡46/23,072(0.20%),阿司匹林组3/8,061(0.04%;p=0.005),阿司匹林组心脏相关死亡率约低5倍。
核心结论
- 全关节置换术后使用阿司匹林预防静脉血栓栓塞可能降低死亡风险。
- 鉴于当前指南允许多种静脉血栓栓塞预防选择,骨科医生在选择预防药物时应了解阿司匹林的潜在额外获益。
研究设计与样本
- 回顾性研究,纳入2000至2017年31,133例初次全关节置换术患者。
- 按静脉血栓栓塞预防方案分为阿司匹林组(25.9%,8,061例)和非阿司匹林组(74.1%,23,072例)。
- 死亡率通过每半年更新的机构死亡数据库评估,采用单变量和多变量回归分析。
主要发现
- 全关节置换术后30天总体死亡率为0.2%,1年总体死亡率为0.6%。
- 阿司匹林使用与30天死亡风险降低独立相关(OR 0.39;p=0.020),与1年死亡风险降低独立相关(OR 0.51;p=0.004)。
- 非阿司匹林组30天死亡风险约为阿司匹林组的3倍(0.3% vs 0.1%;p=0.004),1年死亡风险约为阿司匹林组的2倍(0.7% vs 0.3%;p<0.001)。
- 1年时非阿司匹林组主要死因为心脏相关(46/23,072,0.20%),阿司匹林组心脏相关死亡率为3/8,061(0.04%;p=0.005),约低5倍。
- 1年死亡风险因素包括较高年龄(p<0.001)、男性(p=0.020)、充血性心力衰竭病史(p=0.003)、脑血管疾病(p<0.001)、恶性肿瘤(p<0.001)及既往心肌梗死病史(p<0.001)。
关键数值与推荐
- 证据等级:治疗性III级。
临床怎么用
- 作者认为全关节置换术后使用阿司匹林预防静脉血栓栓塞可能降低死亡风险。
- 作者建议骨科医生在选择静脉血栓栓塞预防药物时了解阿司匹林的潜在额外获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of aspirin as prophylaxis against venous thromboembolism (VTE) following total joint arthroplasty (TJA) has increased in popularity; however, the potential cardioprotective effects of aspirin when administered as VTE prophylaxis remain unknown. The present study investigated the influence of VTE prophylaxis, including aspirin, on mortality following TJA. METHODS: We retrospectively reviewed 31,133 patients who underwent primary TJA from 2000 to 2017. Patient demographics, body mass index, and comorbidities were obtained from an electronic chart query. Patients were allocated into 2 cohorts on the basis of the VTE prophylaxis administered: aspirin (25.9%, 8,061 patients) and non-aspirin (74.1%, 23,072 patients). Mortality was assessed with use of an institutional mortality database that is updated biannually. Univariate and multivariate regression analyses were performed. RESULTS: The overall mortality rate was 0.2% and 0.6% at 30 days and 1 year after TJA, respectively. The use of aspirin was independently associated with lower risk of death at both 30 days (odds ratio [OR], 0.39; p = 0.020) and 1 year (OR, 0.51; p = 0.004). Patients in the non-aspirin cohort showed 3 times the risk of death at 30 days compared with the aspirin cohort (0.3% compared with 0.1%; p = 0.004), and twice the risk of death at 1 year (0.7% compared with 0.3%; p < 0.001). At 1 year, the primary cause of death in the non-aspirin group was cardiac-related (46 of 23,072, 0.20%). In the aspirin group, the rate of cardiac-related death was almost 5 times lower (3 of 8,061, 0.04%; p = 0.005). Risk factors for mortality at 1 year included higher age (p < 0.001), male sex (p = 0.020), history of congestive heart failure (p = 0.003), cerebrovascular disease (p < 0.001), malignancy (p < 0.001), and history of prior myocardial infarction (p < 0.001). CONCLUSIONS: The present study demonstrates that the use of aspirin as prophylaxis against VTE following TJA may reduce the risk of mortality. Given the numerous options available and permitted by the current guidelines, orthopaedic surgeons should be aware of the potential added benefits of aspirin when selecting a VTE-prophylactic agent. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Rondon AJ, Shohat N, Tan TL, et al. The Use of Aspirin for Prophylaxis Against Venous Thromboembolism Decreases Mortality Following Primary Total Joint Arthroplasty. J Bone Joint Surg Am. 2019. PMID: 30893231. doi:10.2106/JBJS.18.00143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。